ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Myotonic Dystrophy Type 1 (DM1) Market Research Report 2024
Published Date: April 2024
|
Report Code: QYRE-Auto-5X11171
Home | Market Reports | Health| Pharmacy
Global Myotonic Dystrophy Type 1 DM1 Market Research Report 2022
BUY CHAPTERS

Global Myotonic Dystrophy Type 1 (DM1) Market Research Report 2024

Code: QYRE-Auto-5X11171
Report
April 2024
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Dyne
Pfizer Inc
Vertex
Lupin Ltd
AMO Pharma
Expansion Therapeutics
Audentes
PepGen
NeuBase Therapeutics
Harmony Biosciences

Myotonic Dystrophy Type 1 (DM1) Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Myotonic Dystrophy Type 1 (DM1) Market

Myotonic Dystrophy Type 1 (DM1) Market

The global Myotonic Dystrophy Type 1 (DM1) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Type 1 (DM1), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Type 1 (DM1).

Report Scope

The Myotonic Dystrophy Type 1 (DM1) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myotonic Dystrophy Type 1 (DM1) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myotonic Dystrophy Type 1 (DM1) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Myotonic Dystrophy Type 1 (DM1) Market Report

Report Metric Details
Report Name Myotonic Dystrophy Type 1 (DM1) Market
CAGR 5%
Segment by Type
  • Exondys
  • Emflaza
  • Translarna
Segment by Application
  • Hospitals
  • Clinics
  • Home Care
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Dyne, Audentes, Pfizer, Vertex, PepGen, NeuBase Therapeutics, Lupin, AMO Pharma, Expansion Therapeutics, Harmony Biosciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Myotonic Dystrophy Type 1 (DM1) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Myotonic Dystrophy Type 1 (DM1) Market report?

Ans: The main players in the Myotonic Dystrophy Type 1 (DM1) Market are Dyne, Audentes, Pfizer, Vertex, PepGen, NeuBase Therapeutics, Lupin, AMO Pharma, Expansion Therapeutics, Harmony Biosciences

What are the Application segmentation covered in the Myotonic Dystrophy Type 1 (DM1) Market report?

Ans: The Applications covered in the Myotonic Dystrophy Type 1 (DM1) Market report are Hospitals, Clinics, Home Care

What are the Type segmentation covered in the Myotonic Dystrophy Type 1 (DM1) Market report?

Ans: The Types covered in the Myotonic Dystrophy Type 1 (DM1) Market report are Exondys, Emflaza, Translarna

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Myotonic Dystrophy Type 1 (DM1) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Perspective (2019-2030)
2.2 Myotonic Dystrophy Type 1 (DM1) Growth Trends by Region
2.2.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Myotonic Dystrophy Type 1 (DM1) Historic Market Size by Region (2019-2024)
2.2.3 Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Region (2025-2030)
2.3 Myotonic Dystrophy Type 1 (DM1) Market Dynamics
2.3.1 Myotonic Dystrophy Type 1 (DM1) Industry Trends
2.3.2 Myotonic Dystrophy Type 1 (DM1) Market Drivers
2.3.3 Myotonic Dystrophy Type 1 (DM1) Market Challenges
2.3.4 Myotonic Dystrophy Type 1 (DM1) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myotonic Dystrophy Type 1 (DM1) Players by Revenue
3.1.1 Global Top Myotonic Dystrophy Type 1 (DM1) Players by Revenue (2019-2024)
3.1.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Players (2019-2024)
3.2 Global Myotonic Dystrophy Type 1 (DM1) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myotonic Dystrophy Type 1 (DM1) Revenue
3.4 Global Myotonic Dystrophy Type 1 (DM1) Market Concentration Ratio
3.4.1 Global Myotonic Dystrophy Type 1 (DM1) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Type 1 (DM1) Revenue in 2023
3.5 Myotonic Dystrophy Type 1 (DM1) Key Players Head office and Area Served
3.6 Key Players Myotonic Dystrophy Type 1 (DM1) Product Solution and Service
3.7 Date of Enter into Myotonic Dystrophy Type 1 (DM1) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myotonic Dystrophy Type 1 (DM1) Breakdown Data by Type
4.1 Global Myotonic Dystrophy Type 1 (DM1) Historic Market Size by Type (2019-2024)
4.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Type (2025-2030)
5 Myotonic Dystrophy Type 1 (DM1) Breakdown Data by Application
5.1 Global Myotonic Dystrophy Type 1 (DM1) Historic Market Size by Application (2019-2024)
5.2 Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
6.2 North America Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
6.4 North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
7.2 Europe Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
7.4 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
8.2 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2019-2024)
8.4 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
9.2 Latin America Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
9.4 Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size (2019-2030)
10.2 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024)
10.4 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dyne
11.1.1 Dyne Company Detail
11.1.2 Dyne Business Overview
11.1.3 Dyne Myotonic Dystrophy Type 1 (DM1) Introduction
11.1.4 Dyne Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.1.5 Dyne Recent Development
11.2 Audentes
11.2.1 Audentes Company Detail
11.2.2 Audentes Business Overview
11.2.3 Audentes Myotonic Dystrophy Type 1 (DM1) Introduction
11.2.4 Audentes Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.2.5 Audentes Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Myotonic Dystrophy Type 1 (DM1) Introduction
11.3.4 Pfizer Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Myotonic Dystrophy Type 1 (DM1) Introduction
11.4.4 Vertex Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.4.5 Vertex Recent Development
11.5 PepGen
11.5.1 PepGen Company Detail
11.5.2 PepGen Business Overview
11.5.3 PepGen Myotonic Dystrophy Type 1 (DM1) Introduction
11.5.4 PepGen Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.5.5 PepGen Recent Development
11.6 NeuBase Therapeutics
11.6.1 NeuBase Therapeutics Company Detail
11.6.2 NeuBase Therapeutics Business Overview
11.6.3 NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Introduction
11.6.4 NeuBase Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.6.5 NeuBase Therapeutics Recent Development
11.7 Lupin
11.7.1 Lupin Company Detail
11.7.2 Lupin Business Overview
11.7.3 Lupin Myotonic Dystrophy Type 1 (DM1) Introduction
11.7.4 Lupin Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.7.5 Lupin Recent Development
11.8 AMO Pharma
11.8.1 AMO Pharma Company Detail
11.8.2 AMO Pharma Business Overview
11.8.3 AMO Pharma Myotonic Dystrophy Type 1 (DM1) Introduction
11.8.4 AMO Pharma Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.8.5 AMO Pharma Recent Development
11.9 Expansion Therapeutics
11.9.1 Expansion Therapeutics Company Detail
11.9.2 Expansion Therapeutics Business Overview
11.9.3 Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Introduction
11.9.4 Expansion Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.9.5 Expansion Therapeutics Recent Development
11.10 Harmony Biosciences
11.10.1 Harmony Biosciences Company Detail
11.10.2 Harmony Biosciences Business Overview
11.10.3 Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Introduction
11.10.4 Harmony Biosciences Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
11.10.5 Harmony Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Dyne
Pfizer Inc
Vertex
Lupin Ltd
AMO Pharma
Expansion Therapeutics
Audentes
PepGen
NeuBase Therapeutics
Harmony Biosciences
List of Tables
    Table 1. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Exondys
    Table 3. Key Players of Emflaza
    Table 4. Key Players of Translarna
    Table 5. Global Myotonic Dystrophy Type 1 (DM1) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Region (2019-2024)
    Table 9. Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Region (2025-2030)
    Table 11. Myotonic Dystrophy Type 1 (DM1) Market Trends
    Table 12. Myotonic Dystrophy Type 1 (DM1) Market Drivers
    Table 13. Myotonic Dystrophy Type 1 (DM1) Market Challenges
    Table 14. Myotonic Dystrophy Type 1 (DM1) Market Restraints
    Table 15. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Players (2019-2024)
    Table 17. Global Top Myotonic Dystrophy Type 1 (DM1) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Type 1 (DM1) as of 2023)
    Table 18. Ranking of Global Top Myotonic Dystrophy Type 1 (DM1) Companies by Revenue (US$ Million) in 2023
    Table 19. Global 5 Largest Players Market Share by Myotonic Dystrophy Type 1 (DM1) Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Myotonic Dystrophy Type 1 (DM1) Product Solution and Service
    Table 22. Date of Enter into Myotonic Dystrophy Type 1 (DM1) Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2019-2024)
    Table 26. Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2025-2030)
    Table 28. Global Myotonic Dystrophy Type 1 (DM1) Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2019-2024)
    Table 30. Global Myotonic Dystrophy Type 1 (DM1) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2025-2030)
    Table 32. North America Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 33. North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
    Table 34. North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
    Table 35. Europe Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
    Table 37. Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 39. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2019-2024) & (US$ Million)
    Table 40. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region (2025-2030) & (US$ Million)
    Table 41. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 42. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
    Table 43. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
    Table 44. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country (2025-2030) & (US$ Million)
    Table 47. Dyne Company Detail
    Table 48. Dyne Business Overview
    Table 49. Dyne Myotonic Dystrophy Type 1 (DM1) Product
    Table 50. Dyne Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 51. Dyne Recent Development
    Table 52. Audentes Company Detail
    Table 53. Audentes Business Overview
    Table 54. Audentes Myotonic Dystrophy Type 1 (DM1) Product
    Table 55. Audentes Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 56. Audentes Recent Development
    Table 57. Pfizer Company Detail
    Table 58. Pfizer Business Overview
    Table 59. Pfizer Myotonic Dystrophy Type 1 (DM1) Product
    Table 60. Pfizer Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 61. Pfizer Recent Development
    Table 62. Vertex Company Detail
    Table 63. Vertex Business Overview
    Table 64. Vertex Myotonic Dystrophy Type 1 (DM1) Product
    Table 65. Vertex Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 66. Vertex Recent Development
    Table 67. PepGen Company Detail
    Table 68. PepGen Business Overview
    Table 69. PepGen Myotonic Dystrophy Type 1 (DM1) Product
    Table 70. PepGen Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 71. PepGen Recent Development
    Table 72. NeuBase Therapeutics Company Detail
    Table 73. NeuBase Therapeutics Business Overview
    Table 74. NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Product
    Table 75. NeuBase Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 76. NeuBase Therapeutics Recent Development
    Table 77. Lupin Company Detail
    Table 78. Lupin Business Overview
    Table 79. Lupin Myotonic Dystrophy Type 1 (DM1) Product
    Table 80. Lupin Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 81. Lupin Recent Development
    Table 82. AMO Pharma Company Detail
    Table 83. AMO Pharma Business Overview
    Table 84. AMO Pharma Myotonic Dystrophy Type 1 (DM1) Product
    Table 85. AMO Pharma Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 86. AMO Pharma Recent Development
    Table 87. Expansion Therapeutics Company Detail
    Table 88. Expansion Therapeutics Business Overview
    Table 89. Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Product
    Table 90. Expansion Therapeutics Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 91. Expansion Therapeutics Recent Development
    Table 92. Harmony Biosciences Company Detail
    Table 93. Harmony Biosciences Business Overview
    Table 94. Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Product
    Table 95. Harmony Biosciences Revenue in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024) & (US$ Million)
    Table 96. Harmony Biosciences Recent Development
    Table 97. Research Programs/Design for This Report
    Table 98. Key Data Information from Secondary Sources
    Table 99. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Myotonic Dystrophy Type 1 (DM1) Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Type: 2023 VS 2030
    Figure 3. Exondys Features
    Figure 4. Emflaza Features
    Figure 5. Translarna Features
    Figure 6. Global Myotonic Dystrophy Type 1 (DM1) Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Application: 2023 VS 2030
    Figure 8. Hospitals Case Studies
    Figure 9. Clinics Case Studies
    Figure 10. Home Care Case Studies
    Figure 11. Myotonic Dystrophy Type 1 (DM1) Report Years Considered
    Figure 12. Global Myotonic Dystrophy Type 1 (DM1) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Myotonic Dystrophy Type 1 (DM1) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Region: 2023 VS 2030
    Figure 15. Global Myotonic Dystrophy Type 1 (DM1) Market Share by Players in 2023
    Figure 16. Global Top Myotonic Dystrophy Type 1 (DM1) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Type 1 (DM1) as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Myotonic Dystrophy Type 1 (DM1) Revenue in 2023
    Figure 18. North America Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
    Figure 20. United States Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Canada Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
    Figure 24. Germany Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. France Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. U.K. Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Italy Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Russia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Nordic Countries Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Share by Region (2019-2030)
    Figure 32. China Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Japan Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. South Korea Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Southeast Asia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. India Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Australia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Latin America Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
    Figure 40. Mexico Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Brazil Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Share by Country (2019-2030)
    Figure 44. Turkey Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Saudi Arabia Myotonic Dystrophy Type 1 (DM1) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Dyne Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 47. Audentes Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 48. Pfizer Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 49. Vertex Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 50. PepGen Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 51. NeuBase Therapeutics Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 52. Lupin Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 53. AMO Pharma Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 54. Expansion Therapeutics Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 55. Harmony Biosciences Revenue Growth Rate in Myotonic Dystrophy Type 1 (DM1) Business (2019-2024)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
    Figure 58. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global RANKL Inhibitors Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-35Z18485
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Morphine Test Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-28M18423
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Compound Antibacterial Agent for Animal - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-38V14855
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Antipyretic Stickers Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-22E8302
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions